Ecdysterone vs Exemestane
Moderate Research vs FDA Approved
avoid Mechanism-based · 64% Both Ecdysterone and Exemestane carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently.
Molecular Data
Ecdysterone Exemestane
Weight 480.64 Da 296.40 Da
Half-life ~4-9 hours ~24 hours
Type Ecdysteroid (C27H44O7) Steroidal aromatase inhibitor (irreversible, suicide inhibitor)
Key Benefits
Ecdysterone
01 Activation of muscle protein synthesis through ERbeta/PI3K/Akt/mTOR signaling without androgen receptor binding
02 Statistically significant increases in lean muscle mass demonstrated in a controlled human trial in trained subjects
03 No hormonal suppression -- does not affect testosterone, LH, or FSH levels, eliminating the need for post-cycle therapy
04 No androgenic side effects (no hair loss, acne, prostate issues, or virilization in women)
05 No hepatotoxicity, unlike oral anabolic steroids that undergo 17-alpha alkylation
06 Naturally occurring in common foods (spinach, quinoa), with a long history of safe dietary exposure
07 Compatible with other performance compounds due to its non-hormonal mechanism
08 Available as a dietary supplement without prescription in most jurisdictions
Exemestane
01 Irreversible aromatase inactivation eliminates estrogen rebound upon discontinuation
02 Steroidal structure with mild androgenic activity may offset some low-estrogen side effects
03 Potent estrogen suppression (85-95% reduction in estradiol at full dose)
04 Compatible with tamoxifen (unlike anastrozole, no pharmacokinetic interference)
05 Prevents gynecomastia during testosterone or aromatizable steroid cycles
06 Reduces estrogen-driven water retention, bloating, and blood pressure elevation
07 Oral dosing with once-daily or less frequent administration for cycle support
Dosing Protocols
Ecdysterone
500-1000 mg/day (oral) or 50-100 mg/day (injectable) / 1-2x daily
Enhanced Anabolic Effect / Higher Bioavailability 50-100 mg/day Once daily
Exemestane
12.5mg EOD or 25mg E3D (estrogen management) / Every other day to every 3 days (cycle support); daily (breast cancer)
Side Effects
Ecdysterone
Mild gastrointestinal discomfort (nausea, bloating, or stomach upset) with oral doses, particularly at higher dosages taken without food
Injection site pain, redness, or mild swelling with injectable administration
Exemestane
Joint pain and stiffness (generally less severe than with anastrozole due to mild androgenic activity)
Fatigue and general malaise
Hot flashes or flushing
Mood changes (irritability, flat affect, low mood)
Headache
Increased sweating
Contraindications
Known allergy to ecdysteroids or spinach-derived compounds
Pregnancy and breastfeeding (insufficient safety data)
Individuals with estrogen-sensitive conditions should consult a physician, though ERbeta activation is generally considered protective rather than proliferative
Known hypersensitivity to exemestane or any excipients
Premenopausal women (not indicated and potentially harmful to reproductive function)
Pregnancy or breastfeeding (teratogenic risk)
Severe hepatic impairment
Pre-existing severe osteoporosis or high fracture risk
Concurrent use with other aromatase inhibitors (anastrozole, letrozole)
Research Evidence
Ecdysterone Exemestane
Status Moderate Research FDA Approved
References 5 studies 5 studies
Latest 2020 —
FDA Approved No Yes
More comparisons: Testosterone
This comparison is for educational and research purposes only. Consult a healthcare professional before use.